Predicting treatment response based on RNA expression in large datasets

Research output: Contribution to journalArticle

Abstract

PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.

Original languageEnglish (US)
Pages (from-to)1443-1445
Number of pages3
JournalClinical Cancer Research
Volume25
Issue number5
DOIs
StatePublished - Mar 1 2019

Fingerprint

Clinical Trials
RNA
Neoplasms
Datasets

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Predicting treatment response based on RNA expression in large datasets. / Mansfield, Aaron; Jen, Jin.

In: Clinical Cancer Research, Vol. 25, No. 5, 01.03.2019, p. 1443-1445.

Research output: Contribution to journalArticle

@article{f9e05fb1dd2b4b91a269f28ff945ef29,
title = "Predicting treatment response based on RNA expression in large datasets",
abstract = "PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.",
author = "Aaron Mansfield and Jin Jen",
year = "2019",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-18-2823",
language = "English (US)",
volume = "25",
pages = "1443--1445",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Predicting treatment response based on RNA expression in large datasets

AU - Mansfield, Aaron

AU - Jen, Jin

PY - 2019/3/1

Y1 - 2019/3/1

N2 - PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.

AB - PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.

UR - http://www.scopus.com/inward/record.url?scp=85062292114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062292114&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-2823

DO - 10.1158/1078-0432.CCR-18-2823

M3 - Article

C2 - 30446588

AN - SCOPUS:85062292114

VL - 25

SP - 1443

EP - 1445

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -